Gulf War Illness is a constellation of chronic multisymptom illnesses born from the 1990 -1991 Persian Gulf War, operationally identified as Desert Shield/Desert Storm. During Operation Desert Shield/Storm, 700,000 U.S. Service Members deployed to the Persian Gulf to liberate Kuwait in response to Iraqi annexation. The toxicants that service members endured included anthrax/botulinum vaccinations, oil well fires, chemical/biological weapons, depleted uranium, noise, Chemical Agent Resistant Coating (CARC), pyridostigmine bromide (PB), pesticides, sand, dust, particulates, toxic embedded fragments, infectious diseases, heat injuries, and occupational hazards.
The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) is a collaborative research group promoting an innovative, efficient and evidence-based process to perform clinical trials in veterans with Gulf War Illness. Led by Dr. Nancy Klimas, the team combines extensive experience in neuro-immunology, clinical trials, and program management to advance understanding and treatment for veterans suffering from this complex illness.
Mechanisms of Oxidative Stress during Antioxidant Treatment in Gulf War Illness: N-Acetyl Cysteine (NAC): This mechanistic, multi-site study utilizes antioxidant NAC to assess oxidative stress levels in Persian Gulf War veterans.
Visit ClinicalTrials.gov for study record details.
Phase II, Placebo-Controlled Study of BacoMind ® Bacopa Monnieri Standardized Extract in Gulf War Illness: This double-blind, phase II study aims to measure the cognitive effect of nutraceutical Bacopa on central nervous system symptoms of GWI, likely attributed to chemical and environment exposures during wartime efforts.
Visit ClinicalTrials.gov for study record details.
For more information, contact us at 954-262-2870 or GWICTIC@nova.edu. If you are interested in joining a Gulf War Illness trial, please complete the Recruitment Registry form.